Exchange
Date | Category
File | Description |
|---|
| BSE 17-Feb-2022 | Outcome
FILE | Un-Audited Financial Results For The Quarter Ended 31St December 2021
Un-Audited Financial Results for the Quarter ended 31st December 2021 |
| BSE 14-Feb-2022 | Outcome
FILE | Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th February 2022
Board Meeting the Board of Directors of the Company has considered and approved the following items along with other items at their meeting held today on February 14 2021: i. Unaudited Financial Results for the quarter and nine months ended December 31 2021; andii. Limited Review Report given by the Statutory Auditor of the Company for the quarter and nine months ended December 31 2021 ; |
| BSE 09-Feb-2022 | Intimation
FILE | Board Meeting Intimation for The Meeting Of The Board Of Directors Of The Company Will Be Held On Monday 14Thfebruary 2022 At New Delhi.
MESCO PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve 1. To consider and approve the standalone unaudited financial results for the quarter ended on 31st December 2021 along with Limited Review Reports. 2. Any other business with the permission of the Chairman. |
| BSE 03-Jan-2022 | Intimation
FILE | Closure of Trading Window
As per the Securities and Exchange Board of India (Prohibition of Insider Trading)(Amendment) Regulations 2018 (including Second Amendment in the said Regulations dated July 25 2019) the Trading restriction period" shall be made applicable from the end of every quarter till 48 hours after the declaration of Financial Results. In view of the aforesaid it is hereby intimated that the trading window of the Company would be closed with immediate effect i.e. immediately on close of Trading Hours on BSE on Friday December 31 2021 and shall be opened on 48 hours after declaration Unaudited Financial Results of the Company for the quarter ended on December 31 2021 along with along the Limited Review Report thereon. |
| BSE 15-Nov-2021 | General Announcements
FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Unaudited Financial Results for the Quarter ended 30th September 2021 |
| BSE 12-Nov-2021 | Outcome
FILE | Un-Audited Financial Results For The Quarter Ended 30Th September 2021
Un-Audited Financial Quarterly Results with Limited Review Report for 30th September 2021 |
| BSE 12-Nov-2021 | Outcome
FILE | Board Meeting Outcome for Outcome Of Board Meeting Dated 12Th November 2021
Considered and approved the Un-Audited Financial Results for Quarter ended on 30th September 2021 as per Regulation 33(3) of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 along with the Limited Review Report. |
| BSE 09-Nov-2021 | General Announcements
FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 please find enclosed the newspaper publication for Board Meeting of the Company to be held on Friday the 12th November 2021 . |
| BSE 08-Nov-2021 | Intimation
FILE | Board Meeting Intimation for Board Meeting Intimation For Consider And Approve The Standalone Unaudited Financial Results For The Quarter Ended On 30Th September 2021 Along With Limited Review Reports
MESCO PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 inter alia to consider and approve The standalone unaudited financial results for the quarter ended on 30th September 2021 along with Limited Review Reports. |
| BSE 29-Sep-2021 | General Announcements
FILE | Proceedings Of 35Th Annual General Meeting Of The Company
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulations 2015 please find enclosed herewith the summary of proceedings of the 35th Annual General Meeting of the Company held on Wednesday 29th September 2021 at 09:00 A.M. at Upper Kesalton Tallital Nainital-263 001 Uttarakhand. |
| BSE 20-Sep-2021 | General Announcements
FILE | Reg. 34 (1) Annual Report
Annual Report of the Company Mesco Pharmaceuticals Limited for the year ended 31.03.2021 |
| BSE 13-Sep-2021 | General Announcements
FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities Exchange and Board of India (LODR) Regulations 2015 (SEBI Listing Regulations) please find enclosed Newspaper Advertisement for the convening of 35th Annual General Meeting of the Company in Financial Express English Edition and Shah Times in Hindi Edition. |
| BSE 10-Sep-2021 | Intimation
FILE | Fixes Book Closure for AGM
Mesco Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 24 2021 to September 29 2021 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 29 2021. |
| BSE 08-Sep-2021 | General Announcements
FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Unaudited Result for the quarter ended 30.06.2021 as per Reg 47 |
| BSE 06-Sep-2021 | Outcome
FILE | Quarterly Results With Limited Review Report For 30Th June 2021
Quarterly Results with Limited Review Report for 30th June 2021 |
| BSE 06-Sep-2021 | Outcome
FILE | Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2021
Pursuant to the applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we would like to inform you that the Board of Directors in their meeting held today i.e. 06th September 2021 have considered and approved the agenda as per attachment. |
| BSE 04-Sep-2021 | Intimation
FILE | Board Meeting Intimation for Consider And Approve The Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2021 Along With Limited Review Reports
MESCO PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2021 inter alia to consider and approve 1. To consider and approve the standalone unaudited financial results for the quarter ended on 30th June 2021 along with Limited Review Reports. 2. Consider matters relating to the ensuing Annual General Meeting |
